Aerie Pharma (AERI) Commences Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan
Tweet Send to a Friend
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) today announced the commencement of patient dosing in its Phase 2 clinical trial designed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
